Reported 2 days ago
H.C. Wainwright analyst Mitchell Kapoor has reiterated a Buy rating for Legend Biotech Corporation (NASDAQ: LEGN), setting a price target of $75. The positive outlook is driven by the company's CARVYKTI treatment, recently approved by the FDA without a risk evaluation strategy, which is expected to enhance its market launch. Despite acknowledging alternatives, the analyst emphasizes the company's potential in the oncology sector.
Source: YAHOO